Form 4: Nascent Biotech Director Acquires 50,000 Shares

Douglas John Karas, a director of Nascent Biotech Inc., acquired 50,000 shares of common stock at $0.10 per share on June 30, 2024, as part of his employment contract.

Summary

• On June 30, 2024, Douglas John Karas, a director of Nascent Biotech Inc., acquired 50,000 shares of the company's common stock.
• The shares were acquired at a price of $0.10 per share.
• This transaction increased Karas's direct holdings to 1,821,552 shares.
• The acquisition was part of Karas's employment contract with Nascent Biotech.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares is generally a good sign, but the context of it being part of an employment contract tempers the enthusiasm.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.
• The acquisition was part of the director's employment contract, suggesting a long-term commitment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Investors often monitor these filings to gauge sentiment and potential future performance.

Stakeholder Impact

• The acquisition could have a slightly positive impact on shareholders, as it signals confidence from a company director.

Key Dates

Keywords

Nascent Biotech, NBIO, Director, Share Acquisition, Form 4, Douglas Karas, Insider Trading